Anti PD‐1, anti PD‐L1, and anti CTLA‐4 immunotherapies have shown the most promising outcomes in the treatment of various malignancies including breast cancer, lung cancer, CRC, and melanoma. This evidence concerns the gene CTLA4 and lung carcinoma.